title: [Combination drug therapy in leprosy].
abstract: The importance of polichemotherapy in multibacilar leprosy (LL and LD) in patients without any previous therapy as in those diagnosticated and under monotherapy most of all in the resistance patients is presented. Sulphones, clofazimine and rifampicine are selected as first rate drugs and protionamide-etionamide as second rate drugs. The therapy plans with the association of two and three drugs and the convenience of continuing indefinitely with at least one of the drugs are presented insisting on the advantages of the clofazimine-sulphones and rifampicine-sulphones associations. The necessity of immunotherapy for recover of celular immunity against the bacilus, is the only form of preventing relapses and drug resistance.
mesh_terms: D002991:Clofazimine / Q000008:administration & dosage; D003622:Dapsone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005000:Ethionamide / Q000008:administration & dosage; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage*; D007918:Leprosy / Q000188:drug therapy*; D011515:Prothionamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage
chemical_list: D007917:Leprostatic Agents; D011515:Prothionamide; D003622:Dapsone; D002991:Clofazimine; D005000:Ethionamide; D012293:Rifampin
vernacular_title: Terapéutica combinada en la lepra.